Leerink Partnrs Analysts Lift Earnings Estimates for Genfit S.A. (NASDAQ:GNFT)

Genfit S.A. (NASDAQ:GNFT) – Equities researchers at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for shares of Genfit in a report released on Thursday, September 19th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of $0.65 per share for the year, up from their previous forecast of $0.52. The consensus estimate for Genfit’s current full-year earnings is $0.56 per share.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Genfit in a research note on Friday.

Genfit Stock Performance

Shares of NASDAQ:GNFT opened at $4.84 on Monday. The company has a current ratio of 2.94, a quick ratio of 2.94 and a debt-to-equity ratio of 0.92. The business’s fifty day moving average price is $4.23 and its two-hundred day moving average price is $4.06. Genfit has a one year low of $2.89 and a one year high of $6.05.

Hedge Funds Weigh In On Genfit

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. boosted its position in Genfit S.A. (NASDAQ:GNFT) by 2,229.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 82,359 shares of the company’s stock after acquiring an additional 78,823 shares during the period. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 at the end of the most recent reporting period. 2.24% of the stock is currently owned by hedge funds and other institutional investors.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.